Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 4 June 2009, Vol. 113, No. 23, pp. 6011-6014.
Prepublished online as a Blood First Edition Paper on March 23, 2009; DOI 10.1182/blood-2008-12-195388.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix
Right arrow All Versions of this Article:
blood-2008-12-195388v1
113/23/6011    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diez-Martin, J. L.
Right arrow Articles by Sureda, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diez-Martin, J. L.
Right arrow Articles by Sureda, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted December 29, 2008
Accepted March 1, 2009

Comparable survival between HIV positive and HIV negative non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

Jose L. Diez-Martin*, Pascual Balsalobre, Alessandro Re, Mariagrazia Michieli, Jose M. Ribera, Carmen Canals, Eulogio Conde, Anne Rosselet, Ian Gabriel, Rosario Varela, Bernardino Allione, Kate Cwynarski, Philippe Genet, Ildefonso Espigado, Pierre Biron, Norbert Schmitz, Anne E. Hunter, Augustin Ferrant, Gaelle Guillerm, Mark Hentrich, Manuel Jurado, Pascual Fernandez, David Serrano, Giuseppe Rossi, and Anna Sureda

Hospital General Universitario Gregorio Maranon, Madrid, Spain
Spedali Civili, Brescia, Italy
Centro di Riferimento Oncologico IRCCS, Aviano, Italy
Institut Catala d'Oncologia-Hosp. Univ. German Trias i Pujol, Badalona, Spain
EBMT Lymphoma Working Party, Barcelona, Spain
Hosp. Univ. Marques de Valdecilla, Univ. de Cantabria, Santander, Spain
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Hammersmith Hospital, London, United Kingdom
Comp. Hosp. Univ. de A Coruna, A Coruna, Spain
H SS Antonio e Biagio, Alessandria, Italy
Royal Free Hospital, London, United Kingdom
Hopital Victor Dupouy, Argenteuil, France
Hosp. Univ. Virgen del Rocio, Sevilla, Spain
Centre Leon Berard, Lyon, France
AK St. Georg, Hamburg, Germany
Leicester Royal Infirmary, Leicester, United Kingdom
Cliniques Universitaires St. Luc, Brussels, Belgium
H Augustin-Morvan, Brest, France
Klinikum Harlaching, Munchen, Germany
Hosp. Univ. Virgen de las Nieves, Granada, Spain
Hosp. Gen. Alicante, Alicante, Spain

* Corresponding author; email: jdiez.hgugm{at}salud.madrid.org.

Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on HAART. We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients. This retrospective EBMT study included 53 patients (66% non-Hodgkin (NHL) and 34% Hodgkin lymphoma (HL)) within each cohort. Both groups were comparable except for the higher proportion of males, mixed cellularity-HL and patients receiving G-CSF prior to engraftment and a smaller proportion receiving TBI-based conditioning within the HIV-Ly cohort. Incidence of relapse, overall and progression-free survival were similar in both cohorts. A higher non-relapse mortality within the first year post-ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly due to early bacterial infections, although this was not statistically significant and did not influence survival. Thus, within the HAART era HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
M. Hentrich, X. Schiel, A. Niedermeier, L. Lutz, R. Rupec, C. Stief, J. Bogner, M. Karthaus, and A. Gerl
Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor
Ann. Onc., November 1, 2009; 20(11): 1900 - 1901.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020